CARASENT ASA: APPROVED PROSPECTUS AND LISTING OF SHARES
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE
SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, HONG
KONG, SOUTH AFRICA, NEW ZEALAND, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN
WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Oslo, May 25, 2021: Reference is made to the stock exchange announcement on
December 11, 2020 where Carasent ASA (the "Company") announced that the Company
had resolved a private placement in connection with the acquisition of Avans
Soma AS (the "Private Placement") The Private Placement was directed towards the
shareholders (sellers) of Avans Soma as consideration for 50 % of the shares in
Avans Soma AS and comprised of 2,211,191 new shares (the "New Shares").
The New Shares were registered on delivered on a separate ISIN NO 001 0915499
(temporary ISIN) and was unlisted pending approval of a listing prospectus (the
"Prospectus") by the Norwegian Financial Supervisory Authority (the "NFSA").
The NFSA has reviewed and approved the Company's prospectus on May 25, 2021
regarding the listing of the New Shares. Following the NSFA approval of the
Prospectus, the New Shares will be transferred to the Company's ordinary ISIN
and will be listed on the Oslo Stock Exchange.
The Prospectus will be made available at: www.carasent.com. The Prospectus will
also be available at the offices of the Company. For further information, please
contact: Johan Lindqvist, Chairman firstname.lastname@example.org +46 733 55 09